PREVIOUS QUESTION:

 

NEXT QUESTION:

 

What is neuroleptic malignant syndrome (NMS)?

ANSWER

Neuroleptic malignant syndrome (NMS) is a rare reaction to antipsychotic drugs that treat schizophrenia, bipolar disorder, and other mental health conditions. It affects the nervous system and causes symptoms like a high fever and muscle stiffness.

The condition is serious, but it’s treatable. Most people who get it make a full recovery when it’s found early.

SOURCES:

Kateon, H. , published online September 2013. Mental Health Clinician

Merck Manual Professional Version: "Neuroleptic Malignant Syndrome."

National Institute of Neurological Disorders and Stroke: "NINDS Neuroleptic Malignant Syndrome Information Page."

National Organization for Rare Disorders: "Neuroleptic Malignant Syndrome."

OrphaNet: "Neuroleptic Malignant Syndrome."

Reviewed by Jennifer Casarella on December 4, 2019

SOURCES:

Kateon, H. , published online September 2013. Mental Health Clinician

Merck Manual Professional Version: "Neuroleptic Malignant Syndrome."

National Institute of Neurological Disorders and Stroke: "NINDS Neuroleptic Malignant Syndrome Information Page."

National Organization for Rare Disorders: "Neuroleptic Malignant Syndrome."

OrphaNet: "Neuroleptic Malignant Syndrome."

Reviewed by Jennifer Casarella on December 4, 2019

NEXT QUESTION:

What older antipsychotic drugs can cause neuroleptic malignant syndrome (NMS)?

WAS THIS ANSWER HELPFUL

"ALEXA, ASK WEBMD"

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.